AlphAIAlphAI — Financial news for AI agents
tradingview.com$TNGX

Tango Therapeutics Reports Q3 2026 Net Loss of $68.4 Million

Tango Therapeutics reported a Q3 2026 net loss of $68.4M, up from a $15.9M profit a year earlier, due to higher expenses and zero collaboration revenue. Cash reserves totaled $977.5M. The company shared promising Phase 1/2 results for vopimetostat combined with daraxonrasib in pancreatic cancer, with an 82% response rate and 88% nine-month survival rate. Tango plans to initiate a Phase 3 trial in 2027 and focus on PRMT5-targeted therapies.

Original reporting
tradingview.com
Published Nov 9, 2026, 12:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tango Therapeutics Reports Q3 2026 Net Loss of $68.4 Million — source image
Source · tradingview.com
Decision brief

The 30-second read

$TNGXBearishMed
01

Why it matters

Earnings miss drives short‑term downside, while trial data may spark longer‑term upside potential.

02

Market read

First disclosure of quarterly results and new trial data; material for biotech traders.

03

What to watch

Cash runway of $977.5M provides ample funding for upcoming Phase 3, reducing near‑term financing risk.

Relevance 8/10Novelty 8/10Timing: today

Background

The article summarizes Tango Therapeutics' Q3 2026 SEC 8‑K filing, highlighting financial results and early clinical data.

Company-level read

Ticker impact

$TNGXBearishHigh confidence
Context

Tango Therapeutics reported Q3 2026 results with a $68.4M net loss and disclosed Phase 1/2 trial data showing strong response rates in pancreatic cancer.

Expected impact

likely pressure as the market prices in the larger loss, tempered by upside from promising trial results

Evidence & confidence

Losses are material and unexpected, but the 82% response rate and 88% PFS signal future value, creating mixed short‑term direction.

Market effects

Sector

Biotech sector may see modest uplift as early‑stage oncology data emerges, but overall sentiment stays cautious due to earnings miss.

Regional

U.S. biotech investors may adjust positions; limited broader market effect.

Global

Limited to investors tracking oncology pipelines and small‑cap biotech stocks.

Counterpoint

What could challenge this read

Despite the loss, the trial's high response rates could justify a short‑term rally on optimism for future approvals.

Key entities

  • Company
    Tango Therapeutics, Inc.

    Biopharmaceutical company developing PRMT5‑targeted therapies.

Read at source← All news

Also covered by

2 outlets

Related articles

$TNGXMedAI 8/10

Tango Therapeutics 3Q 2026: Revenue $0, EPS ($0.39) — 10-Q Summary

Tango Therapeutics reported no revenue in 3Q 2026, down from $53.8M a year earlier, with a net loss of $68.39M. R&D and G&A expenses rose, partially offset by higher interest income. Clinical trials for vopimetostat combinations showed promising results. The company plans a global trial in 2027 and will focus on PRMT5 therapies, reducing its workforce by 14%.

tradingview.com
$TNGXHighAI 9/10

Tango Therapeutics Reports Third Quarter 2026 Financial Results

Tango Therapeutics, Inc. (TNGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights Promising Phase 1/2 data from combination study of vopimetostat plus daraxonrasib presented at 2026 ESMO Congress demonstrated 82% objective response rate (ORR) and 88% 9-month progre

SEC EDGAR 8-K
$TNGXMedAI 8/10

Wedbush raises Tango Therapeutics stock price target on trial data

Wedbush raised Tango Therapeutics' (TNGX) price target to $45 from $39, citing positive trial data for vopimetostat in combination with RayzeBio's inhibitors. The stock has surged 271% over the past year, trading at $24.21 with a $4.06B market cap. Analysts see potential upside of 61% to their consensus target. Other analysts have also raised targets, with H.C. Wainwright at $68 and Stifel at $55.

investing.com
$TNGXMedAI 8/10

Stifel raises Tango Therapeutics stock price target on trial data

Stifel raised its price target for Tango Therapeutics (TNGX) to $55 from $40, maintaining a Buy rating. The company's shares have surged 271% over the past year. Stifel increased its peak sales estimate to $7.1 billion, citing trial data. Tango Therapeutics announced workforce reductions and plans to focus on key therapies, with updates expected in 2027. Other analysts have also raised their price targets, with varying opinions on the stock's valuation.

investing.com